Author

S. P. Delaney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:multiome· 1 Approach:statistical model· 1 Organism:zebrafish· 1

Frequent Co-Authors

W. L. Stanford· 2 shared A. Camacho-Magallanes· 1 shared A. M. Crawley· 1 shared A. Pietrobon· 1 shared A. S. Kristof· 1 shared A. Vranjkovic· 1 shared C. Dore· 1 shared C. L. Cooper· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

W. L. Stanford

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Differential and lasting gene expression changes in circulating CD8 T cells in chronic HCV infection with cirrhosis and related insights on the role of Hedgehog signaling

J. Li, A. Vranjkovic, D. Read, S. P. Delaney, W. L. Stanford, C. L. Cooper, A. M. Crawley

This study examines gene expression changes in CD8 T cells from HCV-infected individuals with varying fibrosis stages, identifying lasting hyperfunction and upregulated Hedgehog signaling in cirrhosis.

bioRxiv · Sep 20, 2023Immunology

Three-dimensional drug screen identifies HDAC inhibitors as therapeutic agents in mTORC1-driven lymphangioleiomyomatosis

A. Pietrobon, J. Yockell-Lelievre, N. Melong, L. J. Smith, S. P. Delaney, N. Azzam, C. Xue, N. Merwin, E. Lian, A. Camacho-Magallanes, C. Dore, G. Musso, L. M. Julian, A. S. Kristof, R. Y. Tam, , W. L. Stanford

A 3D drug screen identified HDAC inhibitors as effective against mTORC1-driven lymphangioleiomyomatosis by reducing invasion and selectively killing TSC2-/- cells.

bioRxiv · Jul 3, 2021Cell Biology